Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$31.82

0.16 (0.51%)

07:35
12/14/16
12/14
07:35
12/14/16
07:35

Jefferies cuts Sarepta target on slower than expected launch

Jefferies analyst Gena Wang cut her price target for Sarepta Therapeutics to $32 from $46 after her due diligence revealed stronger payer pushback and a slower launch for Exondys 51, the company's' recently approved treatment of Duchenne muscular dystrophy. After speaking with four private payers, three Medicaid experts and "several" Duchenne muscular dystrophy experts with "first-hand experience" of Exondys 51, Wang believes the majority of patients being under Medicaid as well as restrictive payer policies could further slow the launch of Exondys 51 in the near term. Based on available data, three of five national and eight of 15 regional managed care organizations have denied or restricted coverage for Exondys 51, the analyst tells investors in a research note. Wang keeps a Hold rating on Sarepta shares.

SRPT Sarepta
$31.82

0.16 (0.51%)

12/01/16
FBCO
12/01/16
NO CHANGE
FBCO
Outperform
UnitedHealth policy for Exondys 51 a positive for Sarepta, says Credit Suisse
Credit Suisse analyst Alethia Young noted that Sarepta (SRPT) shares have been weak since UnitedHealth (UNH) posted its medical benefit policy for the company's DMD drug Exondys 51, but she doesn't see a reason for the weakness. She doesn't think encouraging home infusions limits access and believes the requirement for an every 6 month reauthorization is neither "prohibitive nor concerning" as it is standard with expensive rare disease treatments. She sees the policy as a positive for Sarepta, as having more payers supporting Exondys reimbursement makes it hard for other payers not to do so, and keeps an Outperform rating on Sarepta shares.
12/01/16
RBCM
12/01/16
NO CHANGE
RBCM
Outperform
Sarepta DMD drug still likely to be covered by UnitedHealth, says RBC Capital
RBC Capital analyst Simos Simeonidis said some language in UnitedHealthcare's (UNH) Commercial Drug Policy for Sarepta's (SRPT) Exondys 51 may have "spooked" investors, but he continues to believe that the DMD drug will end up being covered by the insurer. The analyst, who would be a buyer of Sarepta amid this weakness, keeps an Outperform rating on the stock.
11/29/16
BARD
11/29/16
NO CHANGE
Target $102
BARD
Outperform
Baird sees strong launch for Sarepta after surveying neurologists
After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.
11/11/16
LEER
11/11/16
NO CHANGE
Target $55
LEER
Market Perform
Sarepta Exondys 51 launch expectations seem too high for 2017, says Leerink
Leerink analyst Joseph Schwartz believes Sarepta Exondys 51 launch expectations may be too high for 2017. While nothing that a true Duchenne muscular dystrophy prevalence remains unknown, the analyst says that a "start form" number of about 200 patients would need to be provided in early January in order for investors to be confident in 2017 consensus sales estimates of $215M. Additionally, Schwartz points out that based on the price of Exondys 51 per vial, it currently appears that management has underestimated the true price of the drug which they will realize.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.